What Is the Half-Life of Oxycodone?

The elimination half-life of immediate-release oxycodone is roughly three to three and a half hours in most adults. In a study of cancer patients receiving single doses, the mean half-life was about 3 hours after intravenous administration and about 3.5 hours after an oral tablet.¹ That number shifts considerably depending on liver health, kidney function, age, genetics, and drug formulation, so the textbook figure is really a starting point rather than a universal constant.

What “Half-Life” Actually Tells You

A drug’s elimination half-life is the time it takes for the concentration in your blood to drop by half. After one half-life, half the drug remains. After two, a quarter remains. After roughly five half-lives, the drug is considered effectively cleared from the body. For a three-and-a-half-hour half-life, that math puts full clearance somewhere around 17 to 18 hours after a single immediate-release dose. But the half-life is not the same thing as how long the pain relief lasts or how long the drug shows up on a test. Those are related but separate questions, and confusing them is one of the most common misunderstandings around opioid pharmacology.

Immediate-Release Versus Extended-Release Formulations

When people quote a half-life for oxycodone, they are usually talking about the immediate-release form. Extended-release (also called controlled-release) tablets are engineered to release the drug slowly into the gut, and that changes the math. A controlled-release tablet does not change how fast your liver processes oxycodone once it reaches the bloodstream. Instead, it stretches out how long the drug keeps entering the bloodstream from the gut, which makes blood levels decline more gradually after the peak.

Pharmacokinetic modeling of controlled-release oxycodone found two absorption phases: a faster phase with a half-life of absorption around 37 minutes, accounting for roughly 38% of the dose, and a much slower phase with a half-life of absorption around 6.2 hours, responsible for the remaining 62%.² Because the drug is still trickling in while the body is already clearing it, the apparent terminal half-life you measure from blood samples looks longer than with an immediate-release dose. Research has shown that this longer measured half-life from oral formulations reflects slower drug clearance caused by the ongoing slow absorption, not an actual change in how quickly the liver breaks the drug down.³ The practical upshot is that a controlled-release tablet maintains effective blood levels for about 12 hours per dose, compared with roughly 4 to 6 hours for immediate-release, even though the liver’s own processing speed has not changed.

How the Liver Breaks Down Oxycodone

Your liver handles oxycodone through two main chemical pathways, each run by a different enzyme family. The larger pathway uses CYP3A4 (and to a lesser extent CYP3A5) to strip off a piece of the molecule, producing a metabolite called noroxycodone. The smaller pathway uses CYP2D6 to convert oxycodone into oxymorphone, which is itself an active painkiller.⁴ The CYP3A4 route is the workhorse: it processes the majority of each dose. The CYP2D6 route handles a smaller fraction but produces the more pharmacologically interesting metabolite.⁵

Both noroxycodone and noroxymorphone (a downstream metabolite) circulate in the blood at higher concentrations than oxymorphone and stick around longer than oxycodone itself. However, research in animal models showed that these metabolites cross into the brain far less effectively than the parent drug, which is a big part of why oxycodone’s pain-relieving action comes overwhelmingly from oxycodone itself rather than from its breakdown products.⁶

Liver Disease Can Dramatically Extend the Half-Life

Because the liver does nearly all the metabolic heavy lifting, anything that impairs liver function slows oxycodone clearance. In people with advanced liver failure, the picture changes starkly: the half-life of immediate-release oxycodone can stretch to an average of about 14 hours, with a range from roughly 6.4 to 24.6 hours. The drug’s bioavailability also rises by around 40%, meaning a larger share of each oral dose reaches the bloodstream.⁷ Those are not small adjustments. A dose that would be cleared in under four hours in a healthy liver may linger in someone with cirrhosis for the better part of a day. Clinical guidance typically recommends cutting the starting dose to 30-50% of normal for patients with severe liver impairment.

Liver dysfunction also specifically hampers CYP2D6, the enzyme responsible for converting oxycodone to oxymorphone.⁸ While CYP2D6 handles the minor metabolic pathway, the combined slowing of both pathways in liver disease creates a cumulative effect that raises blood levels and prolongs the drug’s action well beyond what the standard half-life would predict.

Kidney Disease Adds Another Layer

Oxycodone’s metabolites are cleared primarily through the kidneys. When kidney function declines, those metabolites build up in the blood, and the half-life of the parent drug itself becomes prolonged. A systematic review of opioid use in chronic kidney disease noted that oxycodone’s half-life is extended in these patients and recommended lower doses.⁹ The same review emphasized that oxycodone’s pain-relieving effect depends mainly on the parent drug rather than the metabolites, which is relevant because it means metabolite accumulation is more of a side-effect and toxicity concern than a pain-relief concern. Someone with compromised kidneys may not notice better pain control from a standard dose, but they could experience more sedation, nausea, or respiratory depression from the buildup.

How Age Changes Clearance

Oxycodone clearance is not constant across the human lifespan. It changes at both ends, dramatically in newborns and more modestly in older adults.

Older Adults

A population pharmacokinetic study found that oxycodone’s elimination half-life increases with age in a gradual, predictable way. The context-sensitive half-time at steady state rose from about 3.8 hours at age 25 to about 4.6 hours at age 85. That may not sound dramatic, but simulations of repeated dosing showed that the elderly accumulated roughly 20% higher oxycodone concentrations than younger adults on the same regimen.¹⁰ In practice, this means an 80-year-old taking the same dose and schedule as a 30-year-old will carry meaningfully more drug in their system at any given time, increasing both effect and risk of side effects like sedation and respiratory depression.

Newborns and Infants

The other end of the age spectrum shows much more striking variation. In extremely preterm neonates, the median elimination half-life of oxycodone was 8.8 hours, roughly two and a half times the adult value. In preterm neonates it was about 7.4 hours, and in full-term neonates about 4.1 hours. By 6 to 24 months of age, the half-life had fallen to about 2 hours, actually shorter than in adults.¹¹ The reason: the liver enzymes that process oxycodone are immature at birth, especially in preterm babies, and they ramp up rapidly over the first months of life. The variability between individual neonates was also much larger than in older children, making dosing in this population particularly challenging.¹²

Drug Interactions That Speed Up or Slow Down Clearance

Because oxycodone depends on CYP3A4 and CYP2D6 for metabolism, anything that blocks or boosts those enzymes changes how fast the drug leaves your body. Strong CYP3A4 inhibitors, such as certain antifungal medications and some HIV antivirals, slow down the dominant metabolic pathway and raise oxycodone blood levels. CYP2D6 inhibitors, including several common antidepressants, block the minor pathway. On their own, blocking either single pathway shifts oxycodone levels to some degree. Blocking both simultaneously is where things get concerning: simultaneous inhibition of CYP3A and CYP2D6 results in significantly increased oxycodone concentrations, and this combination should be avoided.¹³

The reverse also happens. Enzyme inducers, substances that make the liver produce more of these enzymes, can speed up oxycodone clearance to the point where the drug stops working well for pain. Medications such as rifampicin (used for tuberculosis), carbamazepine (used for seizures), and the herbal supplement St. John’s wort are all known to have this effect. The result can be subtherapeutic oxycodone concentrations, meaning someone in pain takes their prescribed dose and gets inadequate relief.¹³ Physiologically based pharmacokinetic modeling has confirmed that both inhibition and induction of CYP3A4 and CYP2D6 can substantially change exposure to oxycodone and its metabolites.¹⁴

Genetic Variation in Drug Metabolism

The CYP2D6 gene is famously variable across the human population. Some people carry gene variants that make them “poor metabolizers,” producing little or no functional CYP2D6 enzyme. Others are “ultrarapid metabolizers” with extra gene copies that churn out more enzyme than average. Because CYP2D6 converts oxycodone to the active metabolite oxymorphone, you might expect these differences to meaningfully change how the drug works. And they do affect the metabolite profile: a study of postoperative patients found that plasma concentrations of oxymorphone relative to oxycodone were lowest in poor metabolizers and highest in ultrarapid metabolizers.¹⁵

Whether those metabolite differences translate to differences in actual pain relief or side effects is less clear. A study of cancer patients found no differences in oxycodone response between CYP2D6 poor or intermediate metabolizers compared to normal metabolizers.¹⁶ This is consistent with the broader understanding that oxycodone’s analgesic effect comes mainly from the parent drug, not from oxymorphone. So while your CYP2D6 status changes which metabolites show up in your blood, it may not change the drug’s half-life or pain relief in a way most people would notice. That said, the picture with CYP3A4 variation, which handles the dominant pathway, is less thoroughly studied and could be more consequential.

Pain Relief Does Not Last as Long as You Might Expect

A common assumption is that if a drug’s half-life is about 3.5 hours, the pain relief should last at least that long and maybe longer. In reality, analgesic duration roughly matches the half-life for immediate-release oxycodone. The same study that established the 3-to-3.5-hour half-life found that the duration of analgesia was approximately 4 hours for both intravenous and oral oxycodone, even though the intravenous form produced faster onset of relief.¹ This makes sense: once blood levels fall below the minimum effective concentration, pain returns, and that happens roughly one to two half-lives after the peak.

Interestingly, the type of pain matters. Research on experimental pain models found that for somatic pain (the sharp, localized kind from skin, muscle, or bone), there was a delay between oxycodone blood levels and the analgesic effect. But for visceral pain (the deep, diffuse kind from internal organs), the analgesic effect tracked blood concentration much more closely with no delay.¹⁷ This is part of why oxycodone has historically been considered particularly useful for visceral pain conditions, though prescribing practices are driven by many other factors as well.

Why Naloxone Timing Matters in an Overdose

Naloxone, the opioid-reversal drug carried by emergency responders and available in many pharmacies, works by knocking opioids off their receptors. But naloxone has its own half-life, and it is short, generally around 30 to 90 minutes depending on the route of administration. That is shorter than oxycodone’s half-life, and much shorter than the effective duration of controlled-release oxycodone. A review of naloxone dosing highlighted the risk of re-narcotization, where someone revived with naloxone slips back into respiratory depression as the naloxone wears off while the opioid is still circulating.¹⁸ This is why emergency guidelines emphasize monitoring after naloxone administration and, in many cases, giving repeat doses or a continuous infusion. The mismatch between naloxone’s brief action and oxycodone’s longer presence in the body is especially dangerous with extended-release formulations, where the drug keeps entering the bloodstream for hours.

Oxycodone and Breastfeeding

The half-life of oxycodone matters in a specific way for nursing parents, because the drug passes into breast milk. The concern is not just whether oxycodone appears in milk (it does) but how much varies from person to person. A pharmacokinetic review of opioids in breast milk noted that individual differences in oxycodone metabolism create uncertainty that cannot be resolved simply by switching to a different opioid, since similar variability exists across the class.¹⁹ A person who metabolizes oxycodone slowly, whether due to genetics, liver function, or drug interactions, will maintain higher blood levels and therefore excrete more into breast milk over a longer period. The standard half-life of 3.5 hours provides a rough guide for timing, but it cannot account for this individual variability.

Routes of Administration Beyond Oral Tablets

Most oxycodone is taken by mouth, but other routes exist and each affects how the drug enters and leaves the body. Sublingual absorption (dissolving under the tongue) bypasses the gut and some of the liver’s first-pass metabolism. A study of sublingual oxycodone found that bioavailability depended heavily on the pH of the formulation: at a higher pH of 9.0, sublingual bioavailability averaged about 70%, compared with about 45% at a lower pH of 4.0.²⁰ Higher bioavailability means more of the drug reaches the bloodstream, which affects both the intensity and duration of its effects even though the liver’s elimination rate remains the same. Intravenous oxycodone, used in hospital settings, skips absorption entirely and produces near-immediate peak levels, then clears on a similar timeline to oral dosing, as reflected in the roughly three-hour IV half-life reported in clinical studies.¹

The Difference Between Half-Life and Detection Time

People searching for the half-life of oxycodone often want to know how long the drug will be detectable, whether for pain management compliance monitoring or pre-employment screening. The half-life gives a rough framework: five half-lives (roughly 17-18 hours for immediate-release) puts the blood level near zero. But standard urine drug tests detect metabolites, not just the parent drug, and those metabolites hang around longer. Noroxycodone and noroxymorphone, the most abundant metabolites in circulation, have elimination half-lives that are longer than oxycodone’s own.⁶ This is why oxycodone can appear on urine tests for two to four days after the last dose in regular users, well beyond what the parent drug’s half-life alone would predict. Individual variation in metabolism, hydration, body composition, and kidney function all stretch or compress that window further.

It is also worth knowing that standard immunoassay urine drug panels (the type used in most workplace testing) screen for “opiates,” a category that historically targeted morphine and codeine. These panels often miss synthetic and semi-synthetic opioids like oxycodone unless a specific oxycodone immunoassay is included. Confirmatory testing by mass spectrometry can identify oxycodone and its metabolites individually, which is the approach used in pain management clinics to verify that patients are taking their prescribed medication as directed.